Payment overview · 2025
General Payments
$2,281.40
76 reported records · 20 companies
Healthcare provider profile · identity verified
Hsiao- Fen Chen, M.D
Allopathic & Osteopathic Physicians|Family Medicine · SAN GABRIEL, CA · NPI 1366483497
Verified facts
What the public records show
CMS Open Payments records show Hsiao- Fen Chen, M.D received $2,281.40 in general payments during 2025 across 76 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Kerendia, Linzess, Paxlovid, Trelegy Ellipta, Trintellix, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $805.53 | 35.3% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $326.39 | 14.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $248.71 | 10.9% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.53 | 7.7% | 10 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $125.00 | 5.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $99.69 | 4.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.15 | 4.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.12 | 2.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.93 | 2.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $43.15 | 1.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $35.00 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.17 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.62 | 1.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.94 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.58 | 1.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $22.99 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.93 | 1.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $22.50 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.08 | 1.0% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.39 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,281.40 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $437.62 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $294.28 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $250.29 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $174.78 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $145.95 | 15 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.34 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $102.76 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $102.76 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $99.69 | 4 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $94.15 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $91.05 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.10 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.12 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $57.50 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $43.15 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $4.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 147 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 327 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 137 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 221 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 213 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
147 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
221 | 40 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
101 | 61 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
327 | 59 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
137 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
221 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
355 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
106 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
213 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1481 | 313 |
| Azithromycin | Azithromycin | 948 | 343 |
| Atorvastatin Calcium | Atorvastatin Calcium | 913 | 198 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 841 | 207 |
| Montelukast Sodium | Montelukast Sodium | 774 | 183 |
| Losartan Potassium | Losartan Potassium | 764 | 152 |
| Raloxifene Hcl | Raloxifene Hcl | 608 | 135 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 571 | 126 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 528 | 139 |
| Meloxicam | Meloxicam | 441 | 122 |
| Vascepa | Icosapent Ethyl | 428 | 80 |
| Mupirocin | Mupirocin | 426 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 103 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 396 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 360 | 76 |
| Gabapentin | Gabapentin | 359 | 84 |
| Jardiance | Empagliflozin | 355 | 61 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 342 | 138 |
| Farxiga | Dapagliflozin Propanediol | 327 | 59 |
| Famotidine | Famotidine | 319 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 59 |
| Celecoxib | Celecoxib | 278 | 63 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 264 | 67 |
| Metformin Hcl | Metformin Hcl | 262 | 63 |
| Simvastatin | Simvastatin | 249 | 38 |
| Clonidine Hcl | Clonidine Hcl | 248 | 77 |
| Atenolol | Atenolol | 244 | 46 |
| Icosapent Ethyl | Icosapent Ethyl | 240 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 50 |
| Linzess | Linaclotide | 221 | 40 |
| Amoxicillin | Amoxicillin | 213 | 83 |
| Trintellix | Vortioxetine Hydrobromide | 213 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 43 |
| Donepezil Hcl | Donepezil Hcl | 198 | 37 |
| Januvia | Sitagliptin Phosphate | 193 | 26 |
| Carvedilol | Carvedilol | 189 | 28 |
| Gemfibrozil | Gemfibrozil | 172 | 41 |
| Cephalexin | Cephalexin | 169 | 75 |
| Hydrocortisone | Hydrocortisone | 168 | 34 |
| Eliquis | Apixaban | 165 | 29 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 157 | 49 |
| Tradjenta | Linagliptin | 157 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 153 | 29 |
| Creon | Lipase/Protease/Amylase | 147 | 26 |
| Omeprazole | Omeprazole | 141 | 46 |
| Kerendia | Finerenone | 137 | 19 |
| Finasteride | Finasteride | 128 | 29 |
| Albuterol Sulfate | Albuterol Sulfate | 127 | 20 |
| Azelastine Hcl | Azelastine Hcl | 126 | 27 |
| Nitroglycerin | Nitroglycerin | 119 | 44 |
| Terazosin Hcl | Terazosin Hcl | 119 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 27 |
| Rybelsus | Semaglutide | 106 | 16 |
| Prolia | Denosumab | 101 | 61 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 100 | 16 |
| Allopurinol | Allopurinol | 99 | 23 |
| Propranolol Hcl | Propranolol Hcl | 93 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 21 |
| Furosemide | Furosemide | 83 | 15 |
| Latanoprost | Latanoprost | 80 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 80 | 16 |
| Trazodone Hcl | Trazodone Hcl | 76 | 14 |
| Ezetimibe | Ezetimibe | 75 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 11 |
| Fluocinonide | Fluocinonide | 69 | 18 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 68 | 23 |
| Ketoconazole | Ketoconazole | 65 | 21 |
| Memantine Hcl Er | Memantine Hcl | 64 | 11 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 11 |
| Alendronate Sodium | Alendronate Sodium | 60 | 17 |
| Levofloxacin | Levofloxacin | 60 | 26 |
| Glimepiride | Glimepiride | 56 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 56 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 55 | 17 |
| Glipizide | Glipizide | 55 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 13 |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Procto-Med Hc | Hydrocortisone | 54 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 53 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 53 | suppressed |
| Cyclosporine | Cyclosporine | 51 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Dutasteride | Dutasteride | 50 | suppressed |
| Prednisone | Prednisone | 50 | 34 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Restasis | Cyclosporine | 43 | suppressed |
| Lidocaine | Lidocaine | 42 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | suppressed |
| Lisinopril | Lisinopril | 41 | 14 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 13 |
| Valsartan | Valsartan | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 36 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 34 | suppressed |
| Proctozone-Hc | Hydrocortisone | 34 | 16 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 30 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 12 |
| Ciclopirox | Ciclopirox | 27 | 14 |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Xiidra | Lifitegrast | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Terconazole | Terconazole | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,281.40 · 76 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, Kerendia, Korlym, LEQEMBI, LEQVIO, LINZESS, MOUNJARO, OTEZLA, PANCREAZE, PAXLOVID, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, ZENPEP, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error